Jejum Glucagon Product Review: Key Attributes vs. Competitors
Abstract: This review evaluates Jejum Glucagon, a synthetic peptide analog for glycemic control, against key competitors. Market data (2023-2030 CAGR 8.5%) highlights rising demand for stable, non-native glucagon analogs. Jejum demonstrates superior thermal stability (40°C for 30 days) vs. native glucagon (24h), but lower receptor binding affinity (EC50 2.1 nM vs. 1.2 nM). Competitor brands (e.g., Xeris, Zealand) offer patented auto-injectors; Jejum lacks delivery device integration. GMP-certified, Jejum’s lyophilized powder ensures logistics stability (2-8°C, 36-month shelf life). Selection criteria prioritize purity (>98% HPLC), aggregation risk, and regulatory status (FDA/EMA pending). Industry trends favor multi-agonist peptides, challenging single-target analogs.